CAPS

Across TCGA pan-cancer cohorts, CAPS mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CAPS data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CAPS mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CAPS expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

PDAC, GBM, and LUAD are the cancer types where CAPS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.391	0.986	<.001	33	view →
GBM	DFS	Median	All	0.625	0.857	<.001	23	view →
LUAD	DFS	Median	All	0.891	1.000	.014	8	view →
LSCC	DFS	Median	All	0.899	0.472	.012	4	view →
UCEC	DFS	Tertile	All	0.976	0.851	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CAPS–PDAC (DFS)

Open the PDAC breakdown →